Comparison of the real-world efficacy and safety of romiplostim and recombinant human thrombopoietin (rhTPO) in chemotherapy-induced thrombocytopenia.

BMC Cancer · 2026 · PMC12958640 · PMID 41629833

Europe PMC DOI

hedged sentence

0.3760

closest p · 7.5× alpha

0.3760

boldest claim

The sentences

did not reach statistical significanceP = 0.376not close (p > 0.1)

83.3% with rhTPO) were able to continue scheduled chemotherapy, although this difference did not reach statistical significance ( P = 0.376).

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.